NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

I'm not following all of the trial screening and trial group selection details. But from a distance it appears to me that it would have been better to not consider progression as part of screening. That would have removed all errors in identification of progression type. Whether someone is pseudo or real progressive, for example, is a lot easier to figure out in the post analysis.

And in the end, do they really want to limit DCVax-L use to patients that do not show some kind of progression. Why?

Is that how it looks, at this point, from your perspective?